This site is intended for healthcare professionals

AbbVie and RegenxBio announce eye care collaboration for RGX 314.

Read time: 1 mins
Last updated:14th Sep 2021
Published:14th Sep 2021
AbbVie and RegenxBio Inc. announced a partnership to develop and commercialize RGX 314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR) and other chronic retinal diseases.
Condition: Age Related Macular Degeneration
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest